A scientific morning session on the new strategy in pain management with high-dose ibuprofen and also addressing osteoporosis with a new form of calcium supplement was held on Saturday, May 18, 2024, in Tajrish Hospital.
In this session, Dr. Rahimi, the medical advisor of the company, presented the prevalence of various types of pain in Iran and the therapeutic protocol for pain relief based on the latest pain management guidelines to a group of esteemed Physical medicine and rehabilitation professors:
- Dr Ali Nazari
- Dr Mansour Raigani
- Dr Mohammad Hassan Bahrami
- Dr Amirhossein Mehdi Kagazi
- Dr Leila Sediqipour
- Dr Masoume Bayat
- Dr Masoumeh Zokhali
- as well as residents.
At the end of this session, the superiority of high-dose ibuprofen produced by Kimia Ara Company under the names of Forimo ER 800 (extended-release ibuprofen 800 mg) and Forimo 600 (ibuprofen 600 mg) in terms of effectiveness and safety compared to commonly used non-steroidal anti-inflammatory drugs (NSAIDs) in Iran, including diclofenac, meloxicam, celecoxib, naproxen, and also low-dose ibuprofen, was discussed based on the latest comparative clinical studies, with positive clinical experience of the esteemed professors regarding the effectiveness and safety of high-dose ibuprofen in relieving pain in various patients.
Furthermore, the introduction of a different calcium supplement by Kimia Ara Company under the brand Bonimags plus was done. The superiority of Bonimags plus supplement in terms of its composition, which, in addition to calcium, contains magnesium, zinc, and vitamins D and C, and its different form in sachets compared to existing calcium supplements, was introduced. The superiority of mineral and vitamin doses in Bonimags plus and its sachet form was examined based on clinical studies, and the esteemed professors of physical medicine and rehabilitation approved the prescription of Bonimags plus for patients with osteoporosis symptoms and muscle disorders.
